PL3344655T3 - Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek - Google Patents

Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek

Info

Publication number
PL3344655T3
PL3344655T3 PL16763663.8T PL16763663T PL3344655T3 PL 3344655 T3 PL3344655 T3 PL 3344655T3 PL 16763663 T PL16763663 T PL 16763663T PL 3344655 T3 PL3344655 T3 PL 3344655T3
Authority
PL
Poland
Prior art keywords
antibodies
treatment
lupus nephritis
nephritis
lupus
Prior art date
Application number
PL16763663.8T
Other languages
English (en)
Polish (pl)
Inventor
Scott Ronald Brodeur
Thomas B. Freeman
Gerald Henry NABOZNY
Meera RAMANUJAM
Paul SCHOLL
Juergen STEFFGEN
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL3344655T3 publication Critical patent/PL3344655T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16763663.8T 2015-09-01 2016-08-31 Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek PL3344655T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
PL3344655T3 true PL3344655T3 (pl) 2024-02-19

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16763663.8T PL3344655T3 (pl) 2015-09-01 2016-08-31 Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek

Country Status (16)

Country Link
US (3) US20170058038A1 (OSRAM)
EP (1) EP3344655B1 (OSRAM)
JP (2) JP2018529661A (OSRAM)
KR (1) KR20180039172A (OSRAM)
CN (1) CN107922501A (OSRAM)
AU (1) AU2016317028B2 (OSRAM)
BR (1) BR112018001907A2 (OSRAM)
CA (1) CA2993996A1 (OSRAM)
CL (1) CL2018000317A1 (OSRAM)
DK (1) DK3344655T5 (OSRAM)
ES (1) ES2969968T3 (OSRAM)
HU (1) HUE063528T2 (OSRAM)
MX (1) MX390653B (OSRAM)
PH (1) PH12018500445B1 (OSRAM)
PL (1) PL3344655T3 (OSRAM)
WO (1) WO2017040566A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20240149979A (ko) * 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
EA202190094A1 (ru) * 2018-06-29 2021-04-21 Бёрингер Ингельхайм Интернациональ Гмбх Антитела против cd40 для применения в лечении аутоиммунного заболевания
KR20210097750A (ko) * 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
ZA936128B (en) 1992-08-21 1995-02-20 Genentech Inc Method for treating a LFA-1 mediated disorder
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
AU2005323515A1 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
ES2354865T3 (es) * 2005-05-26 2011-03-18 Seattle Genetics, Inc. Anticuerpos anti-cd40 humanizados y métodos para utilizarlos.
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
RS57114B1 (sr) * 2010-03-31 2018-06-29 Boehringer Ingelheim Int Anti-cd40 antitela
AU2012249454B2 (en) * 2011-04-29 2016-03-24 Apexigen, Inc. Anti-CD40 antibodies and methods of use
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
EP3344655B1 (en) 2023-07-26
CA2993996A1 (en) 2017-03-09
ES2969968T3 (es) 2024-05-23
MX2018002447A (es) 2018-06-15
JP2021185169A (ja) 2021-12-09
PH12018500445A1 (en) 2018-09-10
DK3344655T5 (da) 2024-10-07
WO2017040566A1 (en) 2017-03-09
BR112018001907A2 (pt) 2018-09-25
DK3344655T3 (da) 2023-10-09
JP2018529661A (ja) 2018-10-11
PH12018500445B1 (en) 2022-08-10
AU2016317028B2 (en) 2021-09-09
US20170058038A1 (en) 2017-03-02
HUE063528T2 (hu) 2024-01-28
KR20180039172A (ko) 2018-04-17
AU2016317028A1 (en) 2018-02-22
MX390653B (es) 2025-03-21
US20190177420A1 (en) 2019-06-13
EP3344655A1 (en) 2018-07-11
CL2018000317A1 (es) 2018-07-20
US20230265203A1 (en) 2023-08-24
CN107922501A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
ZA201708448B (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
IL253802A0 (en) A preparation for the treatment of osteoporosis
IL252568A0 (en) Anti-cd38 antibodies for the treatment of acute myeloid leukemia
ZA201703585B (en) Combination immunotherapy approach for treatment of cancer
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
IL252309B (en) Compressed bicyclic compounds for disease treatment
IL285077A (en) Compounds for the treatment of cancer
IL252849A0 (en) Compressed bicyclic compounds for disease treatment
PL3344655T3 (pl) Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek
EP3137087A4 (en) Estrogen combination for treatment of multiple sclerosis
PT3236960T (pt) Fluralaner para utilização no tratamento da demodicose
IL258593A (en) Compounds for the treatment of subculture disorders
IL248697A0 (en) Methods for purifying antibodies
IL247954A0 (en) Immunoglobulin mobilisation
HUE054300T2 (hu) FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
ZA201907460B (en) Improved protocol for treatment of lupus nephritis
GB201609314D0 (en) Methods of forming compounds
EP3137089A4 (en) Use of ginsenoside m1 for treating lupus nephritis
IL246540A0 (en) Freezeald receptor antibodies for cancer treatment
ZA201704589B (en) Compounds for the treatment of cancer
GB201418268D0 (en) Composition & methods of treatment
GB201418272D0 (en) Composition & methods of treatment